启迪药业(000590) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is expected to be a loss of between 115 million to 149 million CNY, compared to a profit of 25.25 million CNY in the same period last year, indicating a significant decline [2]. - The estimated operating revenue for 2024 is projected to be between 320 million to 350 million CNY, down from 404.65 million CNY in the previous year [2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss of 158 million to 192 million CNY, compared to a loss of 4.65 million CNY in the same period last year, reflecting a decline of approximately 3,297.56% to 4,028.68% [2]. - Basic earnings per share are expected to be a loss of between 0.4802 to 0.6222 CNY per share, compared to earnings of 0.1054 CNY per share in the previous year [2]. Goodwill and Performance Commitments - The estimated goodwill impairment amount is projected to be between 110 million to 125 million CNY due to significant impairment signs identified in the goodwill from the acquisition of Guangdong Xiantong Pharmaceutical Co., Ltd. [5]. - The estimated compensation amount for performance commitments related to Guangdong Xiantong is approximately 45 million to 48 million CNY, as the company failed to meet its performance commitments from April 2022 to December 2024 [5]. Profitability and Cost Concerns - The overall gross profit margin and profitability levels are expected to decline due to a decrease in total operating revenue and rising prices of raw materials [5]. Audit and Investment Risks - The financial data provided in the earnings forecast has not been audited by the accounting firm, and the final figures will be confirmed in the annual report [3]. - The company emphasizes the importance of caution regarding investment risks due to the preliminary nature of the forecast data [6].